VA Doctors One Step Closer to Recommending Cannabis to Veterans

When you're ready to find a cannabis dispensary near you, Budpedia is the dispensary near me directory built around verified listings, real menus, and city-by-city coverage.

House Votes 290-116 to Allow VA Doctors to Recommend Medical Cannabis

In one of the most significant cannabis policy votes of 2026, the U.S. House of Representatives approved an amendment that would authorize Department of Veterans Affairs doctors to issue medical marijuana recommendations to military veterans. The measure passed with strong bipartisan support in a 290-116 vote, signaling a dramatic shift in how Washington views the relationship between cannabis and veteran healthcare.

The amendment, sponsored by Representatives Brian Mast (R-FL), Dave Joyce (R-OH), and Dina Titus (D-NV), was adopted as part of the Military Construction, Veterans Affairs, and Related Agencies (MilConVA) appropriations legislation. If enacted in the final spending bill, it would end a longstanding VA directive that has prevented VA healthcare providers from helping veterans access state-legal medical cannabis programs.

What the Amendment Actually Changes

Under current VA policy, clinicians are prohibited from recommending medical marijuana to veterans, even in states where medical cannabis is legal. VA providers can discuss marijuana use as part of comprehensive care planning and adjust treatment plans accordingly, but they cannot actively recommend marijuana or help patients register for state medical cannabis programs.

This creates an awkward situation for millions of veterans. A veteran being treated at a VA facility for chronic pain, PTSD, or another qualifying condition must seek a separate, private-sector healthcare provider to obtain a cannabis recommendation — often at personal expense and without the benefit of having their recommending physician connected to their primary medical record. The VA provider managing their overall care is effectively walled off from a treatment option their patient may already be using.

The Mast-Joyce-Titus amendment would remove this barrier by preventing the VA from enforcing the directive that blocks providers from assisting veterans with medical cannabis. VA doctors could recommend medical marijuana where state law permits, discuss cannabis as a treatment option alongside other therapies, and help veterans navigate state registration requirements.

Importantly, the amendment does not require VA doctors to recommend cannabis — it simply allows them to do so when they believe it's clinically appropriate. The decision remains a medical judgment call between the veteran and their healthcare provider, consistent with how other treatment recommendations work within the VA system.

Why Veterans Are a Unique Population for Cannabis Policy

The veteran community occupies a distinct position in the cannabis discussion, shaped by the specific health challenges that military service produces and the limitations of conventional treatments for those conditions.

Chronic pain is pervasive among veterans, driven by musculoskeletal injuries sustained during service, the physical demands of military training and deployment, and the cumulative wear of years of active duty. The VA has been one of the largest prescribers of opioid painkillers in the country, and the consequences of that approach — addiction, overdose, and the complex challenge of opioid tapering — have made finding alternatives a genuine clinical priority.

Post-traumatic stress disorder (PTSD) affects an estimated 10 to 15 percent of veterans who served in recent conflicts, and treatment options remain limited. Conventional PTSD treatments — cognitive processing therapy, prolonged exposure therapy, and medications like SSRIs — work well for some veterans but leave others with persistent symptoms. Cannabis, while not an FDA-approved PTSD treatment, has been widely reported by veterans as helpful for managing hyperarousal, insomnia, anxiety, and nightmares.

Traumatic brain injury (TBI) is another condition prevalent among veterans, particularly those exposed to blast injuries. The neuroinflammatory and neuroprotective properties of cannabinoids — documented in a growing body of research — make cannabis a subject of legitimate scientific interest for TBI management.

Military service also carries elevated risks for insomnia, anxiety disorders, substance use disorders, and suicidal ideation. For a population that faces barriers to accessing civilian healthcare and that disproportionately relies on the VA system, being unable to discuss cannabis as a treatment option with their primary provider represents a meaningful gap in care.

The Political Landscape

The 290-116 vote margin is itself remarkable. Cannabis-related amendments have historically faced resistance in the House, with many failing on close or party-line votes. The strong bipartisan support for the veterans access amendment reflects several converging political dynamics.

Veterans policy is one of the few remaining areas of genuine bipartisan cooperation in Congress. Both parties view support for veterans as a political imperative, and measures framed as improving veteran healthcare tend to attract cross-party support that other cannabis measures cannot.

The amendment's sponsor list is strategically designed to inoculate against partisan attacks. Representative Mast is a combat-wounded veteran and Republican; Representative Joyce is a Republican who has been a consistent advocate for cannabis reform; Representative Titus is a Democrat from Nevada, a state with both a large veteran population and a mature legal cannabis market. The bipartisan trio makes it difficult for opponents to frame the amendment as a partisan issue.

Additionally, the amendment's language is narrowly tailored. It doesn't legalize cannabis federally, doesn't change VA prescribing authority (since marijuana remains unprescribable under federal law), and doesn't require any provider to do anything. It simply removes a bureaucratic prohibition that prevents willing doctors from helping willing patients. This narrow framing limits the attack surface for opponents.

What Veterans Organizations Say

Major veterans organizations have broadly supported measures to expand cannabis access for veterans, though with varying levels of enthusiasm and specificity.

The Disabled American Veterans (DAV) has supported research into cannabis for veteran healthcare and has advocated for removing barriers that prevent VA providers from discussing cannabis with patients. The Veterans of Foreign Wars (VFW) has similarly called for expanded research and access.

Individual veterans and veteran advocacy groups have been among the most effective voices in the cannabis reform movement, testifying before Congress, sharing personal stories about how cannabis has helped them manage service-connected conditions, and organizing politically to support access measures.

The credibility that military service lends to cannabis advocacy has been an important factor in shifting public and political opinion. When a decorated combat veteran describes how cannabis helped them manage chronic pain and reduce opioid dependence, the message carries a weight that abstract policy arguments cannot match.

What Still Needs to Happen

The House vote is an important milestone, but the amendment is not yet law. It was adopted as part of an appropriations bill, which must still be reconciled with the Senate's version of the same spending legislation. Senate appropriations bills may or may not include similar language, and the conference committee process that reconciles the two chambers' versions can add, modify, or remove provisions.

Even if the amendment survives the legislative process and is signed into law, implementation would require the VA to update its internal policies, train providers, and develop clinical guidelines for cannabis recommendations. Given the VA's institutional culture and bureaucratic processes, this transition could take months to years, depending on leadership priorities and administrative will.

There's also the broader federal landscape to consider. Cannabis remains a Schedule III substance following the rescheduling process initiated by President Trump's December 2025 executive order. While Schedule III status is less restrictive than the previous Schedule I classification, it still means cannabis is a controlled substance subject to federal regulation. The interaction between VA provider recommendations and federal scheduling creates legal and regulatory questions that would need to be resolved.

The Broader Significance

The House vote on veterans and medical cannabis represents more than a policy adjustment. It reflects a fundamental shift in how American institutions are approaching cannabis — moving from reflexive prohibition toward pragmatic evaluation of potential benefits and risks.

For the roughly 9 million veterans enrolled in VA healthcare, the amendment offers the prospect of having their cannabis use integrated into their overall care rather than existing as a shadow treatment their providers can't acknowledge. For the cannabis reform movement, it provides a powerful proof point: if the federal government trusts its own doctors to recommend cannabis to the men and women who served the country, the case for continued prohibition becomes increasingly difficult to sustain.

The 290-116 vote suggests that this argument is landing. Whether it survives the full legislative process remains to be seen, but the direction of travel is unmistakable.